Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 1

Interventions

pembrolizumab 182Magnetic Resonance Spectroscopy 163Specimen Handling 135enzalutamide 126Nivolumab 124Gemcitabine 99Docetaxel 96Radiosurgery 92Prednisone 85Androgen Antagonists 82Abiraterone Acetate 81Radiotherapy 75apalutamide 68Cisplatin 65darolutamide 63Ipilimumab 63Biopsy 60abiraterone 58Carboplatin 56cabozantinib 55Leuprolide 53enfortumab vedotin 49Radiation 48Pluvicto 45Standard of Care 44atezolizumab 40Surveys and Questionnaires 39acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 37X-Rays 37avelumab 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
gadopiclenol × Genitourinary × 1 year × Clear all
NCT06226129 2025-10-20

Gadopiclenol in Contrast Enhanced MRI of the Prostate

Columbia University

Phase 4 Recruiting
150 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡